Mylan N.V. (MYL) Raised to Buy at ValuEngine
ValuEngine upgraded shares of Mylan N.V. (NASDAQ:MYL) from a hold rating to a buy rating in a research report released on Monday.
Several other research firms have also commented on MYL. Royal Bank Of Canada reaffirmed a hold rating and set a $41.00 price target on shares of Mylan N.V. in a research report on Tuesday, June 13th. Cantor Fitzgerald assumed coverage on shares of Mylan N.V. in a research report on Friday, June 16th. They set a neutral rating and a $41.00 price target for the company. BidaskClub raised shares of Mylan N.V. from a strong sell rating to a sell rating in a research report on Friday, June 16th. Zacks Investment Research raised shares of Mylan N.V. from a sell rating to a hold rating in a research report on Tuesday, August 1st. Finally, Cowen and Company reaffirmed a hold rating and set a $43.00 price target on shares of Mylan N.V. in a research report on Thursday, August 3rd. One equities research analyst has rated the stock with a sell rating, nine have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. Mylan N.V. has an average rating of Buy and a consensus price target of $42.21.
Mylan N.V. (NASDAQ:MYL) traded up 0.98% during mid-day trading on Monday, reaching $38.29. 6,280,817 shares of the company were exchanged. The company has a market capitalization of $20.53 billion, a PE ratio of 30.95 and a beta of 1.30. Mylan N.V. has a one year low of $29.39 and a one year high of $45.87. The stock has a 50-day moving average price of $31.86 and a 200 day moving average price of $36.48. Mylan N.V. also was the target of some unusual options trading activity on Wednesday. Traders purchased 10,562 put options on the stock. This represents an increase of approximately 461% compared to the average volume of 1,883 put options.
Mylan N.V. (NASDAQ:MYL) last posted its earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.18 by ($0.08). The company had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $3 billion. Mylan N.V. had a net margin of 5.51% and a return on equity of 22.42%. Mylan N.V.’s revenue was up 15.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.16 EPS. Analysts predict that Mylan N.V. will post $4.57 EPS for the current year.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Watch List News and is owned by of Watch List News. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/mylan-n-v-myl-raised-to-buy-at-valuengine/1613527.html.
A number of institutional investors and hedge funds have recently made changes to their positions in MYL. Global X Management Co. LLC grew its holdings in Mylan N.V. by 91.6% during the 1st quarter. Global X Management Co. LLC now owns 3,015 shares of the company’s stock valued at $118,000 after buying an additional 1,441 shares in the last quarter. TLP Group LLC purchased a new stake in Mylan N.V. during the 1st quarter valued at approximately $200,000. Doliver Capital Advisors LP purchased a new stake in Mylan N.V. during the 2nd quarter valued at approximately $201,000. Eagle Global Advisors LLC purchased a new stake in Mylan N.V. during the 2nd quarter valued at approximately $205,000. Finally, Sheaff Brock Investment Advisors LLC purchased a new stake in Mylan N.V. during the 2nd quarter valued at approximately $210,000. 71.97% of the stock is owned by institutional investors and hedge funds.
Mylan N.V. Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with Analyst Ratings Network's FREE daily email newsletter.